Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Bristol-Myers Squibb 1Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Bristol-Myers Squibb 1Q

U.S. and International sales increased 11% to $3.1 billion and $1.7 billion, respectively.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb 1Q

1Q Revenues: $4.8 billion (+11%)

1Q Earnings: $743 million (+16%)

Comments: U.S. and International sales increased 11% to $3.1 billion and $1.7 billion, respectively. Growth in the quarter was led by an increase in Plavix sales, up 16% to $1.7 billion, as well as the virology franchise. Baraclude sales were up 42% to $216 million, Reyataz sales were up 16% to $373 million, and Sustiva sales were $335 million (+15%). R&D expenses were flat at $910 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters